EconPapers    
Economics at your fingertips  
 

Role of NS1 antibodies in the pathogenesis of acute secondary dengue infection

Deshni Jayathilaka, Laksiri Gomes, Chandima Jeewandara, Geethal. S. Bandara Jayarathna, Dhanushka Herath, Pathum Asela Perera, Samitha Fernando, Ananda Wijewickrama, Clare S. Hardman, Graham S. Ogg and Gathsaurie Neelika Malavige ()
Additional contact information
Deshni Jayathilaka: University of Sri Jayewardenepura
Laksiri Gomes: University of Sri Jayewardenepura
Chandima Jeewandara: University of Sri Jayewardenepura
Geethal. S. Bandara Jayarathna: University of Sri Jayewardenepura
Dhanushka Herath: University of Sri Jayewardenepura
Pathum Asela Perera: University of Sri Jayewardenepura
Samitha Fernando: University of Sri Jayewardenepura
Ananda Wijewickrama: National Institute of Infectious Diseases
Clare S. Hardman: Oxford NIHR Biomedical Research Centre
Graham S. Ogg: Oxford NIHR Biomedical Research Centre
Gathsaurie Neelika Malavige: University of Sri Jayewardenepura

Nature Communications, 2018, vol. 9, issue 1, 1-15

Abstract: Abstract The role of NS1-specific antibodies in the pathogenesis of dengue virus infection is poorly understood. Here we investigate the immunoglobulin responses of patients with dengue fever (DF) and dengue hemorrhagic fever (DHF) to NS1. Antibody responses to recombinant-NS1 are assessed in serum samples throughout illness of patients with acute secondary DENV1 and DENV2 infection by ELISA. NS1 antibody titres are significantly higher in patients with DHF compared to those with DF for both serotypes, during the critical phase of illness. Furthermore, during both acute secondary DENV1 and DENV2 infection, the antibody repertoire of DF and DHF patients is directed towards distinct regions of the NS1 protein. In addition, healthy individuals, with past non-severe dengue infection have a similar antibody repertoire as those with mild acute infection (DF). Therefore, antibodies that target specific NS1 epitopes could predict disease severity and be of potential benefit in aiding vaccine and treatment design.

Date: 2018
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-018-07667-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-07667-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-07667-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-19
Handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-07667-z